As CD8+ T cells are known for their exceptional cytotoxic activity to tumor cells (St Paul and Ohashi 2020), overexpression of EIF3C in NPC patients might hinder anti-tumor immune response by potentially suppressing CD8+ T cells. Here, EIF3C is linked to neoplasm.